You are given a text that consists of multiple sentences. Your task is to perform abstractive summarization on this text. Use your understanding of the content to express the main ideas and crucial details in a shorter, coherent, and natural sounding text.

EL SEGUNDO, Calif. & SAN ANTONIO, Texas--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ: NH), a provider of enterprise solutions that help businesses transform complex data into actionable insights, today presented during a poster session at the San Antonio Breast Cancer Symposium (SABCS) new significant findings around the adoption of trastuzumab biosimilars in the treatment of HER2-positive breast cancer and the potential clinical and cost benefits of biosimilars. NantHealths presentation demonstrated that the adoption of trastuzumab biosimilars does not appear to be affected by patient selection, stage of disease, or goals of care. The study examined data from NantHealths Eviti Connect, an evidence-based treatment decision platform that gives providers and payers confidence to prescribe and reimburse high-quality, high-value cancer care. The data was collected from treatment plans submitted from June 2019 through October 31, 2020, for patients with HER2-positive breast cancer. The study looked at the effect of multiple factors on adoption, including physician confidence in biosimilar efficacy and efficacy across stages, practice reimbursement, as well as payer medical policy and redirection. The study results indicate that adoption of trastuzumab biosimilars has increased over time across all stages of breast cancer. The choice of brand over biosimilar does not appear to be based on whether a therapy is curative or palliative (biosimilar use was higher in the curative setting) and trastuzumab biosimilar use in practice increases when payer policy favors that use. Consequently, the data infers an opportunity for payers to successfully redirect providers to biosimilars that offer high-value care at lower costs, when utilizing technology, such as Eviti Connect. Additionally, the adoption of trastuzumab biosimilars is estimated to impact societal savings significantly. These findings are exciting as they show that the oncology community is using biosimilars to provide high-quality cancer care while lowering overall costs. This approach also highlights the opportunity to apply real-world data to understand and improve the delivery of valuable oncology care, said William Flood, MD, Chief Medical Officer, Eviti at NantHealth. Presentation Details Title: Real-world data on the adoption of trastuzumab biosimilars in the treatment of HER2-positive breast cancer Authors: William A. Flood, MD, MS; Tiffany Avery, MD; Vlad Kozlovsky; Neil Margolis, Ph.D.; Sandeep K. Reddy, MD Poster Number: PS9-63 Date and Time: December 9, 2020 at 8 am CT The San Antonio Breast Cancer Symposium, held virtually from December 8-11, 2020, provides information on breast cancer research, creating a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer. About NantHealth, Inc.: NantHealth, a member of the NantWorks ecosystem of companies, provides enterprise solutions that help businesses transform complex data into actionable insights. By offering efficient ways to move, interpret, and visualize complex and highly sensitive information, NantHealth enables customers in healthcare, life sciences, logistics, telecommunications, and other industries to automate, understand, and act on data while keeping it secure and scalable. NantHealths product portfolio comprises the latest technology in payer/provider collaboration platforms for real-time coverage decision support (Eviti and NaviNet); molecular analysis (GPS Cancer); and data solutions that provide multi-data analysis, reporting, and professional services offerings. OpenNMS, a NantHealth subsidiary, helps businesses monitor and manage network health and performance. For more information, visit nanthealth.com, follow us on Twitter, Facebook, and LinkedIn, and subscribe to our blog. Forward-Looking Statement This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words expects, anticipates, believes, intends, estimates, plans, will, outlook and similar expressions. Forward-looking statements are based on managements current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate a complex learning system to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; achieving significant commercial market acceptance for our sequencing and molecular analysis solutions; establish relationships with, key thought leaders or payers key decision makers in order to establish GPS Cancer as a standard of care for patients with cancer; our ability to grow the market for our Systems Infrastructure, and applications; successfully enhancing our Systems Infrastructure and applications to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; bandwidth limitations; our ability to integrate OpenNMS into our operations;; our ability to obtain regulatory approvals; dependence upon senior management; the need to comply with and meet applicable laws and regulations; unexpected adverse events; clinical adoption and market acceptance of GPS Cancer; and anticipated cost savings. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the Securities and Exchange Commission.

Answer: NantHealth Presents Significant Treatment Insights at the 2020 San Antonio Breast Cancer Symposium in a Time of Need with the Pandemics Impact on Cancer Care NantHealths study data shows: Adoption of trastuzumab biosimilars in treatment of HER2-positive breast cancer is significant; does not appear to have been affected by patient selection, stage of disease, or goals of care. Potentially significant clinical and cost benefits of trastuzumab biosimilars use in breast cancer treatment.